Home » About Ocular HSV

Ocular HSV: A leading cause of blindness1,2

Annually in the United States, there are:

~24,000 New Cases of Ocular HSV

~24,000

new cases
of ocular HSV

~34,000 Cases of Recurrence

~34,000

CASES OF
RECURRENCE

~500,000 People with HSV-Related Ocular Disease

~500,000

people WITH
HSV-related
ocular disease

Herpes Simplex Virus Dendritic Epithelial Keratitis

Herpes Simplex Virus Dendritic Epithelial Keratitis

Christopher Rapuano, MD and Joseph Shovlin, OD, FAAO provide their insights on and tips for treating this common form of HSV.

Read now >>

Herpes Simplex Virus Dendritic Epithelial Keratitis. Diagnosis and Management downloadable pdf resource

Herpes Simplex Virus Dendritic Epithelial Keratitis: Diagnosis and Management

Marguerite McDonald, MD, FACS provides insight into diagnosing dendritic epithelial keratitis caused by the herpes simplex virus, and management of this type of ocular infection.

Read now >>

Accessing ZIRGAN

See if your patients are covered with Bausch + Lomb’s formulary tool.

Check our formulary tool
How ZIRGAN works

Learn more about how ZIRGAN works in the eye.

See ZIRGAN in action
Indication

ZIRGAN® (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).

Important Safety Information
  • ZIRGAN is indicated for topical ophthalmic use only.
  • Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN.
  • Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
  • Safety and efficacy in pediatric patients below the age of 2 years have not been established.

Click here for full Prescribing Information for ZIRGAN.

ZIRGAN is a trademark of Laboratoires Théa Corporation used under license.

References: 1. Wang JC, Ritterband DC. Herpes simplex virus (HSV) keratitis. Medscape Website. https://emedicine.medscape.com/article/1194268-overview#a6. Updated November 3, 2017. Accessed August 16, 2018. 2. Young RC, Hodge DO, Liesegang TJ, Baratz KH. Incidence, recurrence, and outcomes of herpes simplex virus eye disease in Olmsted County, Minnesota, 1976–2007: the effect of oral antiviral prophylaxis. Arch Ophthalmol. 2010;128(9):1178–1183.

 

THIS WEBSITE IS INTENDED FOR U.S.
HEALTHCARE PROFESSIONALS ONLY.

Please choose an option below:

I am a healthcare professional
in the U.S.
I am not a U.S.
healthcare professional
Indication

ZIRGAN® (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).

Important Safety Information
  • ZIRGAN is indicated for topical ophthalmic use only.
  • Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN.
  • Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
  • Safety and efficacy in pediatric patients below the age of 2 years have not been established.

Click here for full Prescribing Information for ZIRGAN.

ZIRGAN is a trademark of Laboratoires Théa Corporation used under license.